Article

Design, Synthesis and Evaluation of Novel Phthalimide Derivatives as in Vitro Anti-Microbial, Anti-Oxidant and Anti-Inflammatory Agents

Phoebe F. Lamie 1,*, John N. Philoppes 1, Ahmed O. El-Gendy 2, Lucie Rarova 3 and Jiri Gruz 3

1 Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Beni Suef University, Beni Suef 62514, Egypt; E-Mail: johnPhiloppes@yahoo.com
2 Department of Microbiology & Immunology, Faculty of Pharmacy, Beni Suef University, Beni Suef 62514, Egypt; E-Mail: dr.ahmed Micro@yahoo.com
3 Laboratory of Growth Regulators & Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR & Palacký University, Šlechtitelů 27, 783 71 Olomouc, The Czech Republic; E-Mails: lucie.rarova@upol.cz (L.R.); jiri.gruz@upol.cz (J.G.)

* Author to whom correspondence should be addressed; E-Mail: feby. farag@yahoo.com or ffebi.lamey@pharm.bsu.edu.eg; Tel.: +20-82-266-76; Fax: +20-82-231-7958.

Received: 26 June 2015 / Accepted: 20 August 2015 / Published: 14 September 2015

Abstract: Sixteen new phthalimide derivatives were synthesized and evaluated for their in vitro anti-microbial, anti-oxidant and anti-inflammatory activities. The cytotoxicity for all synthesized compounds was also determined in cancer cell lines and in normal human cells. None of the target derivatives had any cytotoxic activity. (ZE)-2-[4-(1-Hydrazono-ethyl)phenyl]isoindoline-1,3-dione (12) showed remarkable anti-microbial activity. Its activity against Bacillus subtilis was 133%, 106% and 88.8% when compared with the standard antibiotics ampicillin, cefotaxime and gentamicin, respectively. Compound 2-[4-(4-ethyl-3-methyl-5-thioxo-1,2,4-triazolidin-3-yl)phenyl]isoindoline-1,3-dione (13b) and 2-[4-(3-methyl-5-thioxo-4-phenyl-1,2,4-triazolidin-3-yl)phenyl]isoindoline-1,3-dione (13c) had anti-oxidant activity. 4-(N'-{1-[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-phenyl]-ethyldene}-hydrazino)benzenesulfonamide (17c) showed the highest in vitro anti-inflammatory activity of the
tested compounds (a decrease of 32%). To determine the mechanism of the anti-inflammatory activity of 17c, a docking study was carried out on the COX-2 enzyme. The results confirmed that 17c had a higher binding energy score (−17.89 kcal/mol) than that of the ligand celecoxib (−17.27 kcal/mol).

**Keywords:** synthesis; phthalimides; anti-microbial; anti-oxidant; anti-inflammatory

1. Introduction

The most important biological activity properties that have been reported for phthalimide (isoindoline-1,3-dione) derivatives 1 are anti-cancer [1], anti-microbial [2,3], anti-oxidant [4] and anti-inflammatory [5]. According to the World Health Organization (WHO), infectious and parasitic diseases are still the second cause of death worldwide. This is assumed to be due to resistance to the anti-microbial agents used. There are a number of studies showing that compounds bearing a phthalimide core may be a scaffold for designing new anti-microbial agents [2]. On the other hand, oxidation results in free radicals which damage the cell via causing oxidative stress leading to inflammation [6].

A literature search of suitable nuclei of use as anti-oxidant and anti-inflammatory agents, revealed phthalimide was one of these heterocyclic compounds [1,4,5]. The chemical core of phthalimides (-CO-N(R)-CO-) shows they are hydrophobic and this increases their potential to cross biological membranes *in vivo* [7]. To increase the biological activity of phthalimide derivatives, a molecular hybridization approach was used to introduce different pharmacophore subunits such as pyrazoles, diazoles, (oxo and thioxo) triazoles, benzo- (oxazoles, imidazoles and thiazoles) and compounds with the azomethine group (Schiff bases). Earlier described synthons have been reported to have anti-microbial [8], anti-oxidant [9] and anti-inflammatory [10–13] activities, apart from other pharmacological actions like anti-convulsant [14], CNS depressant [15], anti-tumor [1,16], anti-proliferative [17] and anti-pyretic [18] effects.

Inspection of the compounds 2–8 depicted in Figure 1 led us to design and synthesize some new compounds containing mainly a phthalimide core and enhanced by certain pharmacophores. The aim was to find new agents with anti-microbial, anti-oxidant and anti-inflammatory effects. All the obtained new derivatives were tested as anti-microbial agents (G+, G− bacteria and fungi) and studied for their anti-oxidant and anti-inflammatory activities using *in vitro* methods, (Figure 1).

![N-Substituted phthalimide](image_url)

**Figure 1. Cont.**
Figure 1. Representative examples of anti-microbial, anti-oxidant and anti-inflammatory agents and structural rationalization of the newly designed compounds.

2. Results and Discussion

2.1. Chemical Synthesis

The synthetic procedures adopted to obtain the target compounds are depicted in Schemes 1–3. Reaction of 2-(4-acetyl-phenyl)-isoindole-1,3-dione (9), which was prepared according to the reported method [19], with equimolar amounts of primary amine derivatives, namely 1-aminotriazole, 4-amino-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one (4-aminophenazone) and 5-amino-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile in absolute ethanol at reflux temperature for 8 h to give isoindole-1,3-dione derivatives 10a–c. The structure of compounds 10a–c was investigated by elemental and spectral analyses. The IR spectrum of 10c revealed a C≡N stretching band at ʋ 2212 cm⁻¹. The ¹H-NMR spectrum of 10b exhibited three singlet peaks due to two CH₃ and N-CH₃ protons at ʋ 2.1, 2.5 and 2.63, respectively. Moreover, ¹³C-NMR spectrum of 10c showed a peak at ʋ 115.04 corresponding to C≡N.
Compounds 11a–c were prepared by the reaction of 2-(4-acetyl-phenyl)-isoindoline-1,3-dione (9) with o-amino derivatives namely, o-phenylenediamine, o-aminophenol and o-aminothiophenol in refluxing absolute ethanol containing few drops of glacial acetic acid yielding 11a–c in good yields. Spectroscopic data (IR, \(^1\)H-NMR, \(^{13}\)C-NMR and MS) and elemental analysis of compounds 11a–c confirmed their structures. The \(^1\)H-NMR spectra of 11a–c exhibited D\(_2\)O exchangeable singlet peaks at \(\delta\) 3.35–4.45 due to the NH proton, confirming that 11a–c exists as cyclic benzimidazole, dihydrobenzoxazole and dihydrobenzothiazole with isoindoline-1,3-dione. Another NH proton appeared in 11a at \(\delta\) 7.65 corresponding to a benzimidazole that was exchanged with D\(_2\)O (Scheme 1).

\[\text{Scheme 1. Synthesis of compounds 10a–c and compound 11a–c. Reagents and conditions:} \]

\(i\) Ar'NH\(_2\), absolute ethanol, reflux, 8 h, (32%–44%); \(ii\) o-phenylenediamine, o-aminophenol or o-aminothiophenol, absolute ethanol/glacial acetic acid, reflux, 12 h, (26%–46%).

Treatment of 9 with excess hydrazine hydrate 99% in dioxane at reflux temperature afforded 2-[4-(1-hydrazonoethyl)phenyl]isoindoline-1,3-dione (12, 45% yield). All collected data for compound 12 were in accord with the assumed structure. Thus, the absence of C=O group of the parent 9 and the observation of forked peak at \(\bar{\nu}\) 3317 and 3235 cm\(^{-1}\) corresponding NH\(_2\) group in IR spectrum of 12 confirmed its structure. Further the \(^1\)H-NMR spectrum of 12 showed D\(_2\)O exchangeable protons at \(\delta\) 5.79 corresponding to NH\(_2\) protons. Moreover, the absence of the C=O observed in the starting material 9 in \(^{13}\)C-NMR spectrum of 12 confirmed the predicted structure of 12.

Compound 12 was treated with isocyanate and/or isothiocyanate derivatives, e.g., p-chlorophenylisocyanate, ethylisothiocyanate and phenylisothiocyanate in dioxane at reflux temperature to provide the corresponding oxo(or thioxo)triazole derivatives 13a–c rather than semicarbazide or thiosemicarbazide analogues A. The structures of compounds 13a–c were investigated by elemental and spectral analyses. The \(^{13}\)C-NMR spectra of 13a–c revealed peaks at \(\delta\) 70.80–90.03 due to the CH\(_3\)-C of the triazole ring which is not present in the open form A.

The triazole ring was also assembled via reaction of compound 9 with a thiosemicarbazide derivative yielding 14 rather than the open form B. The structure of compound 14 was established through, spectroscopic and elemental analyses data. The \(^{13}\)C-NMR spectrum of 14 showed the presence of the
CH$_3$-C moiety of the thioxotriazole ring at $\delta$ 66.80 that was absent in the starting material 9 or in the thiosemicarbazide derivative B, thus confirming the putative structure 14.

Treatment of 9 with a molar equivalent of benzohydrazide derivative in dioxane at reflux temperature for 7 h, gave N’-{1-[4-(1,3-dioxoindolin-2-yl)phenyl]ethylidene}benzohydrazide (15) as a yellow solid in 48% yield. The structure of compound 15 was confirmed by elemental and spectroscopic analyses. The IR spectrum of 15 showed NH stretching at $\bar{\nu}$ 3330 cm$^{-1}$ apart from a C=O band at $\bar{\nu}$ 1672 cm$^{-1}$. Moreover, the $^1$H-NMR spectrum of 15 revealed the presence of two singlet peaks at $\delta$ 2.56 and 2.64 due to the $\text{syn}$ and $\text{anti}$ CH$_3$ groups around the CH$_3$-C=\(N\) double bond. Also, in the mass spectrum of 15 the molecular ion [M$^+$] ($m/z$ 383) corresponding to the formula C$_{23}$H$_{17}$N$_3$O$_3$ was observed (Scheme 2).

![Scheme 2](image)

**Scheme 2.** Synthesis of triazole derivatives 13a–c, 14 and compound 15. *Reagents and conditions:* (i) NH$_2$NH$_2$, dioxane, reflux, 2 h, (24%); (ii) RNCX, dioxane, reflux, 5 h, (39%–47%); (iii) NH$_2$NHCSNH$_2$, dioxane, reflux, 3 h, (33%); (iv) PhCONHNH$_2$, dioxane, reflux, 7 h, (48%).

Introducing a diazole moiety to compound 16 was achieved by heating 9 with an equimolar quantity of ethylenediamine in refluxing dioxane for 4 h. The IR spectrum of 16 revealed the absence of the C=O group of the parent compound 9. Moreover, aromatization of the diazole ring was confirmed from the $^1$H-NMR spectrum that showed two CH diazole ring protons as doublets at $\delta$ 6.56 and 7.66 with a coupling constant of 8.4 Hz. The mass spectrum of 16 exhibited a molecular ion peak [M$^+$] at ($m/z$ 303) confirming its molecular formula C$_{18}$H$_{13}$N$_3$O$_2$.

Treatment of 9 with hydrochloride salt of phenylhydrazine, p-methanesulfonylphenylhydrazine or p-aminosulfonylphenylhydrazine in a molar ratio (1:1) in refluxing absolute ethanol gave 17a–c in excellent yields. All data for compounds 17a–c were consistent with the proposed structures. Thus, the absence of the C=O group of the parent 9 in IR spectra of 17a–c and the appearance of NH (in 17a–c)
and NH2 (in 17c) stretching bands at $\tilde{\nu}$ 3428–3258 cm$^{-1}$ confirmed the structures of 17a–c. Moreover, the syn and anti CH$_3$ protons were observed at $\delta$ 2.30–2.36 and 2.51–2.63. Further, the NH proton singlet was recorded at $\delta$ 9.87–9.98 that was exchangeable with D$_2$O confirmed structure of the 17a–c (Scheme 3).

**Scheme 3.** Synthesis of compounds 16 and 17a–c. *Reagents and conditions:* 
(i) NH$_2$CH$_2$CH$_2$NH$_2$, dioxane, reflux, 4 h, (26%); 
(ii) 4-R'PhNHNH$_2$.HCl, absolute ethanol, reflux, 5–8 h, (49%–52%).

2.2. Biological Evaluation

2.2.1. Anti-Microbial Activity

Different species of microorganisms have varying degrees of susceptibility to antimicrobials. Further, the pathogenic microbes may develop drug resistance to a particular type of antimicrobial agent on prolonged use. Hence, the antimicrobial sensitivity tests are very useful to determine the level of antimicrobial activity of a particular chemical compound on certain pathogenic microorganisms using agar well diffusion method, (Figure 2).

**Figure 2.** Examples of some activities for compounds 11c, 12, 13a, 13b and 13c against *Bacillus subtilis.*
Table 1. The zone of inhibition (mm) for test compounds *#.

|            | Gram Positive Rods | Gram Positive Cocci | Gram Negative Rods | Yeast |
|------------|---------------------|---------------------|--------------------|-------|
|            | Bacillus subtilis   | Mycobacterium phlei | Enterococcus faecalis | Sarcina lutea | Staphylococcus aureus | Escherichia coli ATCC 25922 | Escherichia coli ATCC 5087 | Psedomonas aeruginosa | Proteus vulgaris | Candida albicans |
| 10a        | 13                  | -                   | -                  | -               | 14                | -                  | -                          | -               | -               | 14              |
| 10b        | 13                  | 15                  | 14.5               | 13              | -                 | 15                | -                          | -               | -               | 16              |
| 10c        | -                   | 15                  | 15                 | -               | -                 | -                 | -                          | -               | 12              | 14              |
| 11a        | 15                  | 13                  | 13                 | 16              | -                 | 14.5              | 13                         | -               | 13              | 14              |
| 11b        | 15                  | 13                  | 13                 | 16.5            | -                 | 14                | 12                         | -               | 12              | 13              |
| 11c        | -                   | 17                  | -                  | -               | 14.5              | -                 | -                          | 13              | -               | 20              |
| 12         | 26                  | 17                  | 23                 | 17.5            | 25                | 16                | 17                         | 17              | 25              | 21              |
| 13a        | 13                  | 14                  | -                  | 15.5            | -                 | 13                | -                          | -               | -               | -               |
| 13b        | 13                  | 15.5                | 13                 | 14              | 14                | 13                | -                          | -               | -               | 14              |
| 13c        | 14                  | 16                  | 16                 | 13.5            | 17.5              | 13                | -                          | -               | 13              | 14              |
| 14         | 16                  | 15                  | 15.5               | 15              | 18                | -                 | -                          | -               | 13              | 12              |
| 15         | 13                  | -                   | -                  | 13.5            | -                 | -                 | -                          | -               | 11              | 17.5            |
| 16         | 12                  | 12                  | -                  | 13              | -                 | -                 | -                          | -               | 12              | 18              |
| 17a        | 11                  | 17                  | 11                 | 12              | -                 | -                 | -                          | -               | 11              | 12              |
| 17b        | 13                  | 11                  | -                  | 13              | -                 | -                 | -                          | -               | 12              | 12              |
| 17c        | -                   | 16                  | -                  | 13              | -                 | -                 | -                          | -               | 13              | -               |
| AMP (a)    | 22                  | 30                  | 42                 | 30              | 54                | 31                | 38                         | 44              | -               | -               |
| CTX (b)    | 25                  | 21                  | 40                 | 22              | 48                | 25                | 42                         | 52              | 30              | 31              |
| CN (c)     | 28                  | 31                  | 36                 | 20              | 40                | 24                | 34                         | 40              | 36              | 39              |
| FLU (d)    | -                   | -                   | -                  | -               | -                 | -                 | -                          | -               | -               | 40              |
| TIO (e)    | -                   | -                   | -                  | -               | -                 | -                 | -                          | -               | -               | 36              |

* All synthesized compounds and control anti-microbial were dissolved in DMSO to give a final concentration of 10 mg/mL and then a 60 µL of each was inoculated into cup in agar media.
# Incubation temperature was 37 ± 1 °C for 24 h. (a) AMP: Ampicillin; (b) CTX: Cefotaxime; (c) CN: Gentamicin; (d) FLU: Fluconazole; (e) TIO: Tioconazole.
Table 2. MIC of samples against different microorganisms (µg/mL) *#.

| Compound No. | Proteus vulgaris | Salmonella typhi | Pseudomonas aeruginosa 9027 | E. coli 25927 | E. coli 5087 | Sarcina lutea | Enterococcus faecalis OS4 | Mycobacterium phlei LMG 2313 | Lactobacillus sakei LMG 2710 | Bacillus subtilis LMG 3242 | Listeria innocua | Staphylococcus aureus ATCC 43300 | Staphylococcus aureus ATCC 60931 | Candida albicans |
|--------------|-----------------|-----------------|-----------------------------|---------------|--------------|---------------|--------------------------|------------------------|------------------------|------------------|------------------------|---------------------|------------------------|------------------|
| 10b          | na              | na              | na                          | na            | na           | na            | na                       | na                     | na                     | na                | na                     | na                  | na                     | na               |
| 11a          | na              | na              | na                          | na            | na           | na            | 100                      | 50                     | 50                     | 25                | na                     | na                  | na                     | na               |
| 11b          | na              | na              | na                          | na            | na           | na            | na                       | 50                     | na                     | na                | na                     | na                  | na                     | na               |
| 11c          | na              | na              | na                          | na            | na           | na            | na                       | na                     | 100                    | na                | na                     | 100                 | na                     | na               |
| 12           | na              | na              | 100                         | na            | na           | 50            | 50                       | 25                     | 200                    | 25                | 100                    | na                  | 100                    | na               |
| 13c          | 200             | na              | 200                         | 200           | na           | 200           | na                       | 200                    | 200                    | 200               | 200                    | na                  | na                     | na               |
| 14           | na              | na              | na                          | na            | na           | na            | na                       | na                     | na                     | na                | na                     | na                  | na                     | na               |
| 16           | na              | na              | na                          | na            | na           | na            | na                       | na                     | na                     | na                | na                     | na                  | na                     | na               |
| 17a          | na              | na              | na                          | na            | na           | na            | na                       | na                     | na                     | na                | na                     | na                  | 25                     | na               |

* All tested compounds and controls were used in a final concentration ranging from (200 µg/mL–0.7 µg/mL). # Incubation temperature was 37 ± 1 °C for 24 h. na: (not active >200 unit).
Candida albicans, Listeria innocua, Bacillus subtilis and Enterococcus faecalis were the most susceptible microorganisms toward the majority of our synthetic chemical compounds, while Escherichia coli, Proteus vulgaris and Sarcina lutea were the most resistant bacteria. Based on the antimicrobial sensitivity determinations, all of our compounds showed marked activity against at least two out of the six tested Gram positive bacteria, where the order of activity was as follows; compound 12 showed the highest activity followed by 13c, 13b, 14, (11a = 11b), 10b, 13a, 17a, (16 = 17b), 11c, 10c, 17c, 15 and finally 10a. Compounds 12, 13c and 13b were able to inhibit all six tested Gram positive bacteria. Only compound 12 showed marked activity against Bacillus subtilis where the percentage activities were 133%, 106% and 88.8% when compared with the standard antibiotics ampicillin, cefotaxime and gentamicin, respectively. Activity against Gram negative bacteria was weak, and only compound 12 was able to inhibit 3/4 tested organisms. Compound 12 also showed its highest activities in Gram negative bacteria against Pseudomonas aeruginosa where the percentage activities were 75% and 57.6% when compared with the standard antibiotics cefotaxime and gentamicin, respectively. The order of activity against Gram negative bacteria was as follows; 12, 11a, 14, 11b, 17a, (11c = 13c = 17c), (10c = 16 = 17b) and finally 15 while compounds 10b, 13a, 13b and 10a failed to show any activity against any of the tested Gram negative bacteria at the tested concentrations. All compounds apart from 13a showed activity against Candida albicans in the following order of activity: 12, 11c, 16, 15, 17a, 10b, 17c, (10a = 10 = 11a = 13b = 14), (11b = 13c) and 17b (Tables 1 and 2).

2.2.2. Anti-Oxidant Activity

Oxygen radical absorbance capacity (ORAC) is the ability of compounds to scavenge free peroxy radicals in vitro. While 10a, 10c and 16 activities were below detection limits (<0.1), 13b and 13c were 18 × (18.385 ± 0.857) and 14 × times (13.506 ± 0.819) more active than Trolox, the hydrophilic derivative of vitamin E (Table 3).

Table 3. Oxygen radical absorbance capacity given as ratio between compound and Trolox on an equimolar basis. Data are expressed as mean ± SD (n = 4).

| Compound | ORAC (Compound/Trolox) |
|----------|------------------------|
| 10a      | <0.1                   |
| 10b      | 0.112 ± 0.007          |
| 10c      | <0.1                   |
| 11a      | 0.751 ± 0.081          |
| 11b      | 0.116 ± 0.004          |
| 11c      | 0.183 ± 0.01           |
| 12       | 8.116 ± 0.343          |
| 13a      | 1.169 ± 0.118          |
| 13b      | 18.385 ± 0.857         |
| 13c      | 13.506 ± 0.819         |
| 14       | 1.511 ± 0.045          |
| 15       | 0.192 ± 0.005          |
| 16       | <0.1                   |
| 17a      | 1.839 ± 0.035          |
| 17b      | 0.129 ± 0.005          |
| 17c      | 0.374 ± 0.007          |
2.2.3. Anti-Inflammatory Activity

The in vitro anti-inflammatory properties of the phthalimide derivatives were studied using ELISA in pretreated Human Umbilical Vein Endothelial Cells (HUVEC) where these compounds could inhibit NF-κB. E-selectin (ELAM) expression was induced by TNFα, which is indicative of NF-κB activation. The observed reduction of ELAM expression on treatment of HUVECs with 30 µM or 50 µM of phthalimide derivatives was significant only for 17c—p-aminosulfone derivative—(decrease of 32%). Slight inhibition of ELAM expression and also cell viability was measured for 10b, 11c, 12, 13a, 13b, 13c, 14, 15, 17b. The results showed confirmed that the NF-κB pathway was targeted by the phthalimide derivatives (Figure 3).

![Figure 3](image)

**Figure 3.** E-Selectin (ELAM) expression in TNFα-induced HUVECs compared to cytotoxicity determined by Calcein AM. Curcumin (10 µM) was used as a positive control.

$1 \times 10^4$ HUVECs/well were seeded into 96-well plates and grown to confluence. 50 µM of phthalimide derivatives were added 30 min prior to application of 10 ng/mL TNFα for another 4 h. The cells were then fixed and ELAM levels analysed by ELISA. At the same time, the compounds were analysed by Calcein AM assay to monitor non-specific substance toxicity.
2.2.4. Cytotoxic Activity

Sixteen phthalimide derivatives (10a–c, 11a–c, 12, 13a–c, 14, 15, 16, 17a–c) were tested for cytotoxicity in three different cancer cell lines derived from various tumors (CEM, MCF7, HeLa), normal human fibroblasts (BJ) and human umbilical vein endothelial cells (HUVEC). Treatment of cancer cell lines and fibroblasts with tested compounds for 72 h resulted in no loss of viability (data not shown). After 24 h, the phthalimide derivatives showed no cytotoxicity towards HUVECs (data not shown).

2.3. Molecular Modeling

Compound 17c had the highest anti-inflammatory effects of all tested compounds. Given that the most important enzymatic system in inflammation is the cyclooxygenase system [20], a molecular modeling study was carried out to investigate the binding conformation for 17c and the active binding site of the COX-2 enzyme. The molecular docking study was done using the crystal structure of COX-2 (protein database [PDB] entry: ID 3LN1) [21], with compound 17c (containing COX-2 pharmacophore moiety –SO2NH2 and celecoxib (6) as the reference ligand. The modelling software which was used for this study was the MOE version 2008.10 (Molecular Operating Environment-Montreal, QC, Canada) [22].

Celecoxib as the ligand used in this study, was flexibly docked to the binding site of the COX-2 enzyme, and the docking conformation that was represented by the lowest energy score value was selected. The newly synthesized compound 17c was docked. The docking study showed that 17c occupied the COX-2 binding site compared to celecoxib (6), (Figure 4).

The binding energy for compound 17c was −17.89 kcal/mol compared to −17.27 kcal/mol for celecoxib (6). Moreover, compound 17c exhibited four hydrogen bonding interactions with Tyr341 (C=O), Arg106 (C=O), Arg499 (S=O), and Gln178 (NH) and amino acids with hydrogen bond lengths (2.75, 2.77, 2.96, and 2.21 Å, respectively), (Table 4 and Figure 4).

| Compound | E-Refine (kcal/mol) | No. of Hydrogen Bonds | Hydrogen Bonding Residues | Distance (Å) |
|----------|---------------------|-----------------------|---------------------------|--------------|
| 17c      | −17.89              | 4                     | Tyr341 (C=O)              | 2.75         |
|          |                     |                       | Arg106 (C=O)              | 2.77         |
|          |                     |                       | Arg499 (S=O)              | 2.96         |
|          |                     |                       | Gln178 (NH)               | 2.21         |
| Celecoxib (6) | −17.27              | 2                     | Leu338 (NH)               | 2.63         |
|          |                     |                       | Gln178 (NH)               | 2.55         |

3. Experimental Section

3.1. General Information

Melting points were determined on an Electrothermal digital melting point apparatus and are uncorrected. (IR spectra were recorded on an R 435 spectrophotometer (Middleton, Madison West, WI, USA) and values were reported in cm⁻¹. ¹H-NMR and ¹³C-NMR were carried out on Bruker Advance III 400 MHz spectrophotometer (Bruker BioSpin AG, Fällanden, Switzerland) for ¹H and 100 MHz for
$^{13}$C with BBFO Smart Probe and Bruker 400 AEON Nitrogen-Free Magnet, using TMS as an internal standard and chemical shifts were recorded in ppm on δ scale, Faculty of Pharmacy, Beni Suef University, Egypt. The electron impact (EI) mass spectra were recorded on a Hewlett Packard 5988 spectrometer (Palo Alto, CA, USA), Microanalyses for C, H and N were carried out on Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA) at the Micro analytical unit of Cairo University, Egypt, and all compounds were within ±0.4% of the theoretical values. Thin-layer chromatography (TLC) was performed on Merck (Darmstadt, Germany) TLC aluminium sheets silica gel 60 F$_{254}$ with detection by UV quenching at 254 nm to follow the course of reactions and to check the purity of products. All reagents and solvents were purified and dried by standard techniques.

Figure 4. Cont.
Figure 4. Binding of celecoxib (6) and the most active compound 17c inside COX-2 active site. (a) 2D Interaction for binding of celecoxib (6) inside COX-2 active site, the most important amino acids are shown together with their respective numbers; (b) 3D interaction of celecoxib (6); (c) 2D interaction for binding of the most active compound 17c inside COX-2 active site, the most important amino acids are shown together with their respective numbers; (d) 3D interaction of 17c.
3.1.1. General Procedure for the Synthesis of Compounds 10a–c

A mixture of 9 (2.65 g, 0.01 mol) and the appropriate primary amine (0.01 mol) was refluxed in absolute ethanol (30 mL) for 8 h. The solid separated on hot was filtered, dried and crystallized from dioxane.

(ZE)-2-{4-[1-(4H-1,2,4-Triazol-4-ylimino)ethyl]phenyl}isoindoline-1,3-dione (10a). Yield 32%; m.p. 222–224 °C; IR (KBr, cm⁻¹): 1785 and 1714 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO-d₆) δ 2.63 (s, 3H, CH₃), 7.64–7.89 (m, 2H, Ar-H), 7.94 (s, 2H, Ar-H), 7.99–8.01 (m, 3H, Ar-H), 8.10–8.24 (m, 3H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 13.50, 124.03, 124.50, 127.54, 129.24, 131.98, 135.33, 136.28, 136.49, 158.80, 167.13; MS (m/z, %): 331 (M⁺, 1.77%), 64 (100%); Anal. Calcd. for C₁₈H₁₃N₅O₂: C, 65.25; H, 3.95; N, 21.14. Found: C, 65.03; H, 4.14; N, 21.30%.

(ZE)-2-{4-[1-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylimino)ethyl]phenyl}isoindoline-1,3-dione (10b). Yield 44%; m.p. 218–220 °C; IR (KBr, cm⁻¹): 1784 and 1714 (2C=O, isoindoline-1,3-dione), 1679 (C=O); ¹H-NMR (DMSO-d₆) δ 2.1 (s, 3H, CH₃), 2.50 (s, 3H, CH₃), 2.63 (s, 3H, CH₃), 7.64–7.89 (m, 3H, Ar-H), 7.95–7.98 (m, 7H, Ar-H), 8.00–8.15 (m, 3H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 15.10, 16.50, 39.32, 122.80, 123.94, 127.29, 127.51, 128.38, 128.80, 129.24, 132.01, 133.29, 135.24, 137.20, 138.08, 150.20, 158.80, 160.70, 167.36; MS (m/z, %): 450 (M⁺, 2.40%), 64 (100%); Anal. Calcd. for C₂₇H₂₂N₄O₃: C, 71.99; H, 4.92; N, 12.44. Found: C, 72.13; H, 4.85; N, 12.29%.

(ZE)-5-{1-[4-(1,3-Dioxoisoxindolin-2-yl)phenyl]ethylideneamino}-3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile (10c). Yield 36%; m.p. 232–234 °C; IR (KBr, cm⁻¹): 2212 (C≡N), 1785 and 1713 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO-d₆) δ 2.1 (s, 3H, CH₃), 2.63 (s, 3H, CH₃), 7.65 (s, 1H, NH, D₂O exchangeable), 7.71, 7.72 (dd, 2H, J = 3.2 Hz, 3.2 Hz, Ar-H), 7.92, 8.01 (dd, 1H, J = 3.2 Hz, 3.2 Hz, Ar-H), 8.09–8.24 (m, 3H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 11.60, 18.40, 92.51, 115.04, 123.80, 123.94, 124.04, 126.20, 127.54, 129.25, 131.98, 132.20, 133.40, 134.59, 150.20, 150.40, 158.40, 167.13; MS (m/z, %): 445 (M⁺, 1.47%), 70 (100%); Anal. Calcd. for C₂₇H₁₉N₅O₂: C, 72.80; H, 4.30; N, 15.72. Found: C, 72.68; H, 4.42; N, 15.63%.

3.1.2. General Procedure for the Synthesis of Compounds 11a–c

A mixture of 9 (2.65 g, 0.01 mol) and the corresponding o-amino derivative (0.01 mol) was refluxed in absolute ethanol (30 mL) containing a catalytic amount of glacial acetic acid (0.5 mL) for 12 h. The solid separated on hot was filtered, dried and crystallized from DMF.

2-{4-[2-Methyl-2,3-dihydro-1H-benzo[d]imidazol-2-yl]phenyl}isoindoline-1,3-dione (11a). Yield 46%; m.p. 292–294 °C; IR (KBr, cm⁻¹): 3447 (broad band, 2NH), 1785 and 1714 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO, d₆) δ 2.09 (s, 3H, CH₃), 3.35 (s, 1H, NH, D₂O exchangeable), 7.22–7.46 (m, 3H, Ar-H), 7.61–7.63 (m, 3H, Ar-H), 7.65 (s, 1H, NH, D₂O exchangeable), 7.71, 7.72 (dd, 2H, J = 3.2 Hz, 3.2 Hz, Ar-H), 7.92, 8.01 (dd, 1H, J = 3.2 Hz, 3.2 Hz, Ar-H), 8.09–8.24 (m, 3H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 26.30, 74.70, 112.91, 117.70, 120.20, 124.03, 127.34, 128.09, 129.75, 131.02, 132.30, 136.72, 169.08; MS (m/z, %): 355 (M⁺, 0.17%), 77 (100%); Anal. Calcd. for C₂₂H₁₇N₃O₂: C, 74.35; H, 4.82; N, 11.82. Found: C, 74.13; H, 4.62; N, 11.80%.
2-[4-(2-Methyl-2,3-dihydrobenzo[d]oxazol-2-yl)phenyl]isoindoline-1,3-dione (11b). Yield 26%; m.p. 229–231 °C; IR (KBr, cm⁻¹): 3470 (NH), 1786 and 1713 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO-d₆) δ 2.46 (s, 3H, CH₃), 4.38 (s, 1H, NH, D₂O exchangeable), 7.64 (d, 3H, J = 8 Hz, Ar-H), 7.99–8.00 (m, 6H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 72.32, 98.21, 113.05, 114.01, 124.03, 126.90, 127.54, 128.20, 131.99, 132.50, 136.29, 136.50, 142.60, 167.13; MS (m/z, %): 356 (M⁺, 0.36%), 309 (100%); Anal. Calcd. for C₂₂H₁₆N₂O₃: C, 74.15; H, 4.53; N, 7.86. Found: C, 74.31; H, 4.62; N, 7.80%.

2-[4-(2-Methyl-2,3-dihydrobenzo[d]thiazol-2-yl)phenyl]isoindoline-1,3-dione (11c). Yield 29%; m.p. >300 °C; IR (KBr, cm⁻¹): 3456 (NH), 1781 and 1714 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO-d₆) δ 2.50 (s, 3H, CH₃), 4.45 (s, 1H, NH, D₂O exchangeable), 7.19 (t, 1H, J = 7.2 Hz, Ar-H), 7.28 (t, 1H, J = 7.2 Hz, Ar-H), 7.50–7.52 (m, 2H, Ar-H), 7.56–7.65 (m, 2H, Ar-H), 7.67–7.94 (m, 4H, Ar-H), 7.98 (d, 2H, J = 8.4 Hz, Ar-H); ¹³C-NMR (DMSO-d₆) δ 27.32, 66.81, 122.48, 123.96, 124.03, 127.53, 127.71, 127.76, 129.24, 129.36, 131.98, 135.25, 135.33, 136.28, 136.49, 167.13; MS (m/z, %): 372 (M⁺, 8.50%), 370 (100%); Anal. Calcd. for C₂₂H₁₆N₂O₂S: C, 70.95; H, 4.33; N, 7.52. Found: C, 70.73; H, 4.35; N, 7.31%.

3.1.3. Synthesis of (ZE)-2-[4-(1-Hydrazonoethyl)phenyl]isoindoline-1,3-dione (12)

To a solution of compound 9 (2.65 g, 0.01 mol) in dioxane (30 mL), hydrazine hydrate 99.99% (0.55 g, 0.011 mol) was added and the reaction mixture was heated at reflux temperature for 2 h. The solid separated while hot was filtered, dried and crystallized from DMF. Yield 24%; m.p. >300 °C; IR (KBr, cm⁻¹): 3317, 3235 (NH₂), 1785 and 1714 (2C=O, isoindoline-1,3-dione); ¹H-NMR (DMSO-d₆) δ 2.23 (s, 3H, CH₃), 5.79 (s, 2H, NH₂, D₂O exchangeable), 7.81–7.99 (m, 4H, Ar-H), 8.07–8.14 (m, 4H, Ar-H); ¹³C-NMR (DMSO-d₆) δ 14.46, 113.60, 125.67, 126.24, 127.13, 128.11, 132.20, 132.73, 150.82, 167.31; MS (m/z, %): 279 (M⁺, 11.71%), 370 (100%); Anal. Calcd. for C₁₆H₁₃N₃O₂: C, 68.81; H, 4.69; N, 15.05. Found: C, 68.67; H, 4.55; N, 14.99%.

3.1.4. General procedure for the Synthesis of Compounds 13a–c

A mixture of 12 (2.79 g, 0.01 mol) and the corresponding isocyanate and/or isothiocyanate derivative (0.01 mol) was refluxed in dioxane (30 mL) for 5 h. The solid separated while hot was filtered, dried and crystallized from DMF/MeOH.

2-{4-[4-(4-Chlorophenyl)-3-methyl-5-oxo-1,2,4-triazolidin-3-yl]phenyl}isoindoline-1,3-dione (13a). Yield 47%; m.p. 254–256 °C; IR (KBr, cm⁻¹): 3299, 3224 (2NH), 1785 and 1714 (2C=O, isoindoline-1,3-dione), 1671 (C=O); ¹H-NMR (DMSO-d₆) δ 2.50 (s, 3H, CH₃), 7.31 (d, 4H, J = 8.8 Hz, Ar-H), 7.34 (d, 4H, J = 8.8 Hz, Ar-H), 7.54–7.67 (m, 1H, Ar-H), 7.88–8.15 (m, 3H, Ar-H), 8.96 (s, 1H, NH, D₂O exchangeable), 11.54 (s, 1H, NH, D₂O exchangeable); ¹³C-NMR (DMSO-d₆) δ 27.70, 87.03, 118.17, 120.31, 120.55, 123.70, 125.86, 127.75, 128.90, 129.12, 130.70, 132.20, 139.20, 156.39, 167.31; MS (m/z, %): 432.5 (M⁺, 0.7%), 104(100%); Anal. Calcd. for C₂₃H₁₇ClN₄O₃: C, 63.82; H, 3.96; N, 12.94. Found: C, 64.02; H, 3.75; N, 13.11%.
2-[4-(4-Ethyl-3-methyl-5-thioxo-1,2,4-triazolidin-3-yl)phenyl]isoindoline-1,3-dione (13b). Yield 39%; m.p. 247-249 °C; IR (KBr, cm\(^{-1}\)): 3259, 3158 (2NH), 1782 and 1713 (2C=O, isoindoline-1,3-dione), 1216 (C=S); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 1.13 (t, 3H, J = 6Hz, CH\(_2\)CH\(_3\)), 7.88-7.98 (m, 5H, Ar-H), 8.06-8.23 (m, 3H, Ar-H), 9.15 (s, 1H, NH, D\(_2\)O exchangeable), 11.54 (s, 1H, NH, D\(_2\)O exchangeable); \(^{13}\)C-NMR (DMSO-\(d_6\)) \(\delta\) 15.03, 37.13, 40.59, 90.03, 123.70, 125.59, 127.38, 128.63, 132.20, 133.06, 147.70, 167.31, 182.18; MS (m/z, %): 366 (M\(^+\), 0.5%), 104 (100%); Anal. Calcd. for C\(_{19}\)H\(_{18}\)N\(_4\)O\(_2\)S: C, 62.28; H, 4.95; N, 15.29. Found: C, 62.41; H, 4.78; N, 15.33%.

2-[4-(3-Methyl-5-thioxo-4-phenyl-1,2,4-triazolidin-3-yl)phenyl]isoindoline-1,3-dione (13c). Yield 42%; m.p. >300 °C; IR (KBr, cm\(^{-1}\)): 3437, 3164 (2NH), 1785 and 1714 (2C=O, isoindoline-1,3-dione), 1217 (C=S); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.50 (s, 3H, CH\(_3\)), 7.15 (t, 1H, J = 7.2 Hz, Ar-H), 7.33 (t, 2H, J = 7.6 Hz, Ar-H), 7.54 (d, 2H, J = 7.2 Hz, Ar-H), 7.88-7.99 (m, 4H, Ar-H), 8.06-8.19 (m, 4H, Ar-H), 9.45 (s, 1H, NH, D\(_2\)O exchangeable), 11.54 (s, 1H, NH, D\(_2\)O exchangeable); \(^{13}\)C-NMR (DMSO-\(d_6\)) \(\delta\) 14.44, 70.80, 123.92, 125.60, 127.36, 127.50, 132.02, 133.02, 133.5, 135.23, 137.63, 139.81, 147.49, 167.39, 179.39; MS (m/z, %): 414 (M\(^+\), 1.25%), 104 (100%); Anal. Calcd. for C\(_{23}\)H\(_{18}\)N\(_4\)O\(_2\)S: C, 66.65; H, 4.38; N, 13.52. Found: C, 66.42; H, 4.17; N, 13.55%.

3.1.5. Synthesis of 2-[4-(3-Methyl-5-thioxo-1,2,4-triazolidin-3-yl)phenyl]isoindole-1,3-dione (14)

To a solution of 9 (2.65g, 0.01 mol) in dioxane (30 mL), thiosemicarbazide (0.91 g, 0.01 mol) was added. The reaction mixture was refluxed for 3 h. The solid separated on hot was filtered, dried and crystallized from DMF/acetone. Yield 33%; m.p. >300 °C; IR (KBr, cm\(^{-1}\)): 3417–3271 (3NH), 1781 and 1707 (2C=O, isoindoline-1,3-dione), 1217 (C=S); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.35 (s, 3H, CH\(_3\)), 7.48 (d, 2H, J = 8.4 Hz, Ar-H), 7.90, 7.91 (dd, 2H, J = 3.6 Hz, 2.8 Hz, Ar-H), 7.94, 7.96 (dd, 2H, J = 8 Hz, 2.8 Hz, Ar-H), 8.04 (s, 1H, NH, D\(_2\)O exchangeable), 8.09 (d, 2H, J = 8 Hz, Ar-H), 8.35 (s, 1H, NH, D\(_2\)O exchangeable), 10.31 (s, 1H, NH, D\(_2\)O exchangeable); \(^{13}\)C-NMR (DMSO-\(d_6\)) \(\delta\) 14.44, 70.80, 123.92, 125.60, 127.36, 127.50, 132.02, 133.02, 133.5, 135.23, 137.63, 139.81, 147.49, 167.39, 179.39; MS (m/z, %): 338 (M\(^+\), 0.22%), 153 (100%); Anal. Calcd. for C\(_{17}\)H\(_{14}\)N\(_4\)O\(_2\)S: C, 60.34; H, 4.17; N, 16.84%.

3.1.6. Synthesis of (ZE)-N'-{1-[4-(1,3-Dioxoindolin-2-yl)phenyl]ethylidene}benzohydrazide (15)

A mixture of 9 (2.65 g, 0.01 mol) and benzohydrazide (1.36 g, 0.01 mol) was refluxed in dioxane (30 mL) for 7 h. The solid separated on hot was filtered, dried and crystallized from propanol. Yield 48%; m.p. 247–249 °C; IR (KBr, cm\(^{-1}\)): 3330 (NH), 1781 and 1704 (2C=O, isoindoline-1,3-dione), 1672 (C=O); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.56, 2.64 (2s, 3H, syn & anti CH\(_3\)), 7.59–7.68 (m, 5H, Ar-H), 7.98–8.10 (m, 8H, Ar-H), 10.85 (s, 1H, NH, D\(_2\)O exchangeable); \(^{13}\)C-NMR (DMSO-\(d_6\)) \(\delta\) 22.70, 123.95, 124.50, 127.30, 127.51, 128.41, 128.79, 129.40, 132.03, 133.11 135.25, 138.09, 147.79, 163.20, 167.36; MS (m/z, %): 383 (M\(^+\), 4.05%), 105 (100%); Anal. Calcd. for C\(_{23}\)H\(_{17}\)N\(_3\)O\(_3\): C, 70.05; H, 4.47; N, 10.96. Found: C, 69.98; H, 4.25; N, 10.97%.
3.1.7. Synthesis of 2-[4-(2-Methyl-2H-imidazol-2-yl)phenyl]isoindole-1,3-dione (16)

To a solution of 9 (2.65 g, 0.01 mol) in dioxane (30 mL), ethylenediamine (0.6 g, 0.01 mol) was added. The reaction mixture was refluxed for 4 h. The solution was allowed to cool; the solid separated was filtered, dried and crystallized from ethanol 95%. Yield (26%); m.p. 215–217 °C; IR (KBr, cm\(^{-1}\)): 1781 and 1704 (2C=O, isoindoline-1,3-dione); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.62 (s, 3H, CH\(_3\)), 6.56 (d, 1H, \(J = 8.4\) Hz, Ar-H), 7.49–7.54 (m, 8H, Ar-H), 7.66 (d, 1H, \(J = 8.4\) Hz, Ar-H); \(^1\)C-NMR (DMSO-\(d_6\)) \(\delta\) 27.32, 66.81, 124.03, 127.53, 128.58, 129.24, 131.98, 135.33, 136.28, 136.49, 167.13; MS (m/z, %): 303 (M\(^+\), 5.6%), 80 (100%); Anal. Calcd. for C\(_{18}\)H\(_{13}\)N\(_3\)O\(_2\): C, 71.28; H, 4.32; N, 13.85. Found: C, 71.08; H, 4.27; N, 14.01%.

3.1.8. General Procedure for the Synthesis of Compounds 17a–c

A mixture of 9 (2.65 g, 0.01 mol) and the corresponding phenyl hydrazine hydrochloride derivative (0.01 mol) was heated at reflux temperature in absolute ethanol (30 mL) for 5–8 h (monitored by TLC). The solid separated on hot was filtered, dried and crystallized from dioxane.

\(2\{-4-[1-(Phenyl-hydrazono)-ethyl]-phenyl\}-isoindole-1,3-dione\) (17a). Yield 49%; m.p. 185–187 °C; IR (KBr, cm\(^{-1}\)): 3355 (NH), 1783 and 1711 (2C=O, isoindoline-1,3-dione); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.30, 2.63 (2s, 3H, syn & anti CH\(_3\)), 7.26–7.45 (m, 3H, Ar-H), 7.47 (d, 1H, \(J = 8.4\) Hz, Ar-H), 7.64 (d, 1H, \(J = 8.8\) Hz, Ar-H), 7.99 (m, 3H, Ar-H), 8.11 (d, 1H, \(J = 8.8\) Hz, Ar-H), 9.87 (s, 1H, NH, D\(_2\)O exchangeable); \(^1\)C-NMR (DMSO-\(d_6\)) \(\delta\) 13.27, 113.34, 119.49, 124.03, 127.53, 128.58, 129.24, 131.98, 132.01, 135.33, 136.28, 139.35, 150.80, 167.49; MS (m/z, %): 355 (M\(^+\), 9.26%), 250 (100%); Anal. Calcd. for C\(_{22}\)H\(_{17}\)N\(_3\)O\(_2\): C, 74.35; H, 4.82; N, 11.82. Found: C, 74.28; H, 4.69; N, 12.03%.

\(2-(4-{1-[(4-Methanesulfonyl-phenyl)-hydrazono]-ethyl}-phenyl)-isoindole-1,3-dione\) (17b). Yield 51%; m.p. 208–210 °C; IR (KBr, cm\(^{-1}\)): 3330 (NH), 1783 and 1714 (2C=O, isoindolne-1,3-dione); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.36, 2.63 (2s, 3H, syn & anti CH\(_3\)), 3.12 (s, 3H, SO\(_2\)CH\(_3\)), 7.42 (d, 1H, \(J = 8.8\) Hz, Ar-H), 7.50 (d, 1H, \(J = 8.2\) Hz, Ar-H), 7.64 (d, 2H, \(J = 8.8\) Hz, Ar-H), 7.96–8.01 (m, 5H, Ar-H), 7.99 (m, 3H, Ar-H), 8.11 (d, 2H, \(J = 8.4\) Hz, Ar-H), 9.98 (s, 1H, NH, D\(_2\)O exchangeable); \(^1\)C-NMR (DMSO-\(d_6\)) \(\delta\) 13.77, 44.73, 112.88, 123.92, 126.42, 127.52, 127.56, 129.15, 130.20, 132.01, 132.10, 135.22, 136.26, 150.26, 167.44; MS (m/z, %): 433 (M\(^+\), 58.21%), 163 (100%); Anal. Calcd. for C\(_{23}\)H\(_{19}\)N\(_3\)O\(_4\)S: C, 63.73; H, 4.42; N, 9.69. Found: C, 63.58; H, 4.66; N, 9.73%.

\(4-(N'\text{-}[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-phenyl]ethylidene-hydrazino)-benzenesulfonamide\) (17c). Yield 52%; m.p. 265–267 °C; IR (KBr, cm\(^{-1}\)): 3428–3258 (NH\(_2\) and NH), 1784 and 1711 (2C=O, isoindolne-1,3-dione); \(^1\)H-NMR (DMSO-\(d_6\)) \(\delta\) 2.34, 2.51 (2s, 3H, syn & anti CH\(_3\)), 7.1 (s, 2H, NH\(_2\), D\(_2\)O exchangeable), 7.36 (d, 2H, \(J = 8.8\) Hz, Ar-H), 7.49 (d, 2H, \(J = 8.8\) Hz, Ar-H), 7.68 (d, 2H, \(J = 8.8\) Hz, Ar-H), 7.96–8.12 (m, 6H, Ar-H), 9.98 (s, 1H, NH, D\(_2\)O exchangeable); \(^1\)C-NMR (DMSO-\(d_6\)) \(\delta\) 13.65, 44.73, 112.88, 123.92, 126.42, 127.52, 127.56, 129.15, 130.20, 132.01, 135.22, 136.26, 150.26, 167.44; MS (m/z, %): 433 (M\(^+\), 58.21%), 163 (100%); Anal. Calcd. for C\(_{23}\)H\(_{19}\)N\(_4\)O\(_4\)S: C, 63.73; H, 4.42; N, 9.69. Found: C, 63.58; H, 4.66; N, 9.73%.
3.2. Biological Testing

3.2.1. Antimicrobial Sensitivity Test Using Agar Diffusion Method (Cup Technique)

The cup plate method is an accepted method when test samples diffuse from the cup through an agar layer in a Petri dish or plate to such an extent that the growth of added microorganisms is completely restricted to a circular area or zone around the cavity containing the solution of an antibiotic substance [23]. The anti-microbial activity was expressed as zone diameter in millimetres, which is measured by a ruler [24].

Microorganisms

Gram-positive organisms used in the study were Staphylococcus aureus LMG 3242, Sarcina lutea, Enterococcus faecalis OS4, Listeria innocua LMG 2710, Mycobacterium pheli and Bacillus subtilis. Gram-negative organisms used were Escherichia coli ATCC 5087, Escherichia coli ATCC 25922, Proteus vulgaris and Pseudomonas aeruginosa. The yeast used was Candida albicans.

Standard Antimicrobials

Gentamicin (CN), Cefotaxime (CTX), Ampicillin (AMP), Fluconazole (FLU) and Tioconazole (TIO) were all prepared in concentration of 10 mg/mL.

Preparation of Sample Stock Solutions

All test samples (10a–c, 11a–c, 12, 13a–c, 14, 15, 16, 17a–c) were dissolved in DMSO to give a final concentration of 10 mg/mL.

Experimental Procedure

Each overnight culture of the tested microorganisms was mixed with Muller Hinton agar media to give a final concentration of 1% microorganism (about 0.5 McFarland) and poured into sterile Petri dishes in a fixed amount of 20 mL under aseptic conditions. A sterile cork borer was used to prepare cups of 10 mm diameter. Test samples and standard drugs with volumes of 60 μL were introduced into the cups using a micropipette. All the plates were kept at room temperature for effective diffusion of the test drug and standard and incubated at 37 ± 1 °C for 24 h. The presence of inhibition zones around the cup indicated antibacterial activity. The diameter of the zone of inhibition was measured and recorded [25]. The percentage inhibition activities of tested compounds relative to standard antibiotics were calculated by applying this equation:

\[
\text{The percentage inhibition} = \frac{(\text{Zone of inhibition of tested compound} - \text{cup diameter})}{\text{(Zone of inhibition of standard antibiotic} - \text{cup diameter})} \times 100
\]
Determination of Minimum Inhibitory Concentration (MIC) Using Agar Dilution Method According to Clinical Laboratory Standards Institute (CLSI)

For each sample, different concentrations were diluted with Muller Hinton agar to give a final concentration ranging from (200 µg/mL–0.7 µg/mL). DMSO was used as negative control plate. All bacterial isolates were subcultured on Brain Heart Infusion agar (B.H.I.A.) and incubated at 37 °C for 24 h [26,27]. Three colonies of each microorganism were suspended in 5 mL saline, and the suspension was adjusted to 0.5 McFarland standards and then diluted 10-fold with saline to give an organism suspension of (1 × 10^6 to 5 × 10^6 CFU/mL). This suspension was then further diluted by putting 1 mL suspension in 9 mL saline to give a final suspension volume of 1 × 10^5 to 5 × 10^5 CFU/mL. A multiple inoculator was used to inoculate the prepared agar plates. A 100 µL (i.e., 10^4 CFU) of the prepared inoculums were put in the well of a multi-inoculator, where each inoculation time by multi-inoculator gave about 10 µL of prepared inoculums per plate (i.e., 10^3 CFU). Each experiment was performed in duplicate. All plates were incubated at 35 °C for 48 h. The results were recorded in terms of MIC, which is the lowest concentration of antimicrobial/antifungal agent causing almost complete inhibition of growth or giving no visible growth.

3.2.2. Anti-Oxidant Testing

Determination of Oxygen Radical Absorbance Capacity (ORAC)

Oxygen radical absorbance capacity (ORAC) was determined as described previously [28]. Briefly, 100 µL of 500 nM fluorescein and 25 µL of diluted solutions of tested compounds were pipetted into each working well of a microplate (96 well) preincubated at 37 °C. 25 µL of 250 mM AAPH was then added and the microplate was shaken for 5 s in a fluorometer Infinite 200 (Tecan, Mannedorf, Switzerland). The fluorescence (Ex. 485 nm, Em. 510 nm) was read every 2 min for 60 min. The net area under the curve was used to calculate ORAC which was expressed as a ratio between tested compound and trolox on an equimolar basis.

3.2.3. Anti-Inflammatory Testing

Cell Culture

Stock solutions (10 mmol/L) of tested compounds were prepared by dissolving an appropriate quantity of each substance in DMSO. Dulbecco’s modified Eagle’s medium (DMEM, RPMI 1640 medium), foetal bovine serum (FBS), l-glutamine, penicillin and streptomycin were purchased from Sigma (St. Louis, MO, USA). Calcein AM was obtained from Molecular Probes (Life Technologies, Carlsbad, CA, USA).

The screening cell lines (T-lymphoblastic leukaemia cell line CEM, breast carcinoma cell line MCF7, cervical carcinoma cell line HeLa and human fibroblasts BJ) were obtained from the American Type Culture Collection (Manassas, VA, USA). CEM cell line were cultured in RPMI 1640 medium and the others in DMEM medium (Sigma); both media supplemented with 10% foetal bovine serum, 2 mmol/L l-glutamine, 10,000 U penicillin and 10 mg/mL streptomycin. The cell lines were maintained
under standard cell culture conditions at 37 °C and 5% CO₂ in a humid environment. Cells were subcultured twice or three times a week using the standard trypsinization procedure.

Human Umbilical Vein Endothelial Cells (HUVEC) were cultured in ECGM medium (Endothelial Cell Growth Medium, Provitro, Berlin, Germany), supplemented with 10% foetal bovine serum (Sigma-Aldrich, Munich, Germany). Cells were maintained under standard cell culture conditions at 37 °C and 5% CO₂ in a humid environment. Cells were subcultured twice or three times a week using the standard trypsinization procedure. HUVECs were a kind gift from Prof Jitka Ulrichová (Medical Faculty, Palacky University, Olomouc, The Czech Republic).

CD62E (E-Selectin, ELAM)-induction Assays

Each well of the 96-well plates were coated with collagen G by applying 200 µL for 15 min at 37 °C. Outer wells (A1-A12, H1-H12, 1-H1 and A12-H12) contained only 200 µL/well medium and served as an evaporation barrier. 1 × 10⁴ HUVECs (Human Umbilical Vein Endothelial Cells) were seeded in each of the other wells in 200 µL medium and grown for 48 h to optimal confluence. Increasing concentrations of compounds were then added to the HUVEC-containing wells in triplicates, and the cells were incubated for 30 min, after which 10 ng/mL TNFα was added per well to stimulate NF-κB, and thus ELAM. After another 4 h incubation, the levels of ELAM in each of the HUVEC-containing wells were determined by enzyme-linked activity assays (ELISAs) as described below.

Cell-Surface ELISA ELAM

Cells were washed once with PBS and fixed with 0.1% glutaraldehyde (Sigma-Aldrich), for 15 min at room temperature. The cells were then washed 3 times with 200 µL per well PBS/0.05% Tween 20, blocked with 200 µL/well 5% BSA/PBS for 1 h, and washed again 3 times with 200 µL per well PBS/0.05% Tween 20. Anti-ELAM-antibody (clone BBA-1, R & D Systems, Minneapolis, MN, USA) diluted 1:5000 in 0.1% BSA/PBS (100µL per well) was then added for 1 h at room temperature and washed 5 times with 200 µL per well PBS/0.05% Tween 20. Subsequently, goat anti mouse-HRP antibody (Sigma-Aldrich) diluted 1:10000 in 0.1% BSA/PBS (100 µL per well) was applied and the cells were incubated for 1 h in the dark at room temperature and, after decanting, washed 5 times with 200 µL per well PBS/0.05% Tween 20. The HRP-activity of the cells in each of the wells was estimated using Fast-OPD (o-phenylenediamine dihydrochloride) (Sigma-Aldrich) assay as described [29] and absorbance was measured at OD₄₉₂nm in a plate reader (Tecan).

3.2.4. Cytotoxicity Testing

For the ELAM expression assay the toxicity of tested compounds was assessed in HUVECs by Calcein AM (Molecular Probes, Invitrogen, Karlsruhe, Germany) cytotoxicity assays in 96-well microtiter plates [30]. 20 µL portions of each of the compound concentrations were added in triplicate to the cells, which were then incubated at 37 °C in an atmosphere containing 5% CO₂ for 4 h, after which Calcein AM solution was added for 1 h according to the manufacturer’s instructions. The fluorescence of viable cells was quantified using a Fluoroskan Ascent instrument (Lab-systems, Vantaa, Finland) reader and on the basis of triplicate experiments the cytotoxic concentrations were calculated. Cytotoxicity of tested
compounds was determined also in HUVEC after 24 h and in CEM, MCF7, HeLa and BJ after 72 h by Calcein AM assays as described above.

Molecular Modeling and Docking

The celecoxib-COX-2 crystal structure was obtained from (PDB: ID 3LN1) [21]. Docking of the ligand was carried out. The root mean square deviation was 0.50 Å. Docking was performed using London dGforce. Force field energy was used to refine the results. The most active compound 17c was docked by MOE after preparation of the selected compound through its 3D protonation and selecting the least energetic conformer. The same docking method used for both ligand and 17c. Amino acid interactions and hydrogen bond lengths were measured and summarized in (Table 4).

4. Conclusions

The tested compounds in this study were evaluated against Gram positive, Gram negative and Fungi. The most active phthalimide derivative as an anti-microbial agent was hydrazonoethyl-phenylisoindoline-1,3-dione 12. Most phthalimide derivatives showed antimicrobial activity with the exception of 10a and 10b and 13a and 10 b on Gram negative bacteria, in addition to 13a which had no action on Candida albicans. None of the tested phthalimide derivatives had any cytotoxic activity. Two, 13b and 13c (ethyl and phenyl isothiocyanate derivatives) had anti-oxidant activity. Phthalimide derivatives had mild anti-inflammatory activity in vitro albeit a strong inhibition of E-selectin by 17c.

Acknowledgments

Phoebe F. Lamie would like to express her deepest thanks to all the members of the NMR center at Beni Suef University, Beni Suef, Egypt for their efforts in analyzing all the prepared compounds. All cytotoxic, anti-inflammatory and anti-oxidant assays were financed by a Czech Ministry of Education grant from the National Program for Sustainability I (LO1204). We thank Jitka Ulrichová for the kind gift of HUVEC cells and Olga Hustáková for excellent technical assistance.

Author Contributions

P.F.L. proposed the subject and carry out the synthesis, purification and characterization of the compounds. J.N.P. conceived the study and participated in its design, results, discussion, and coordination. A.O.E.-G. carried out the anti-microbial screening. L.R. and J.G. carried out the anti-inflammatory, anti-oxidants and cytotoxic assay.

Conflicts of Interest

The authors have no conflict of interest to declare.

References

1. Kamal, A.; Bolla, N.R.; Srikanth, P.S.; Srivastava, A.K. Naphthalimide derivatives with therapeutic characteristics: A patent review. Expert Opin. Ther. Pat. 2013, 23, 299–317.
2. Amin, K.M.; El-masry, A.H.; Mohamed, N.A.; Awad, G.E.A.; Habib, B.S. Synthesis, characterization and anti-microbial activity of some novel isoindole-1,3-dione derivatives. Der Pharm. Chem. 2013, 5, 97–108.

3. El-Gaby, M.S.A.; Zahran, M.A.; Ismail, M.M.F.; Ammar, Y.A.A. A novel Synthesis of dibenzo[c,f]chromenes, dibenzo[c,h]chromenes and benzo[7,8]chromeno[3,4-f]isoindoles as anti-microbial agents. ILFarmaco 2000, 55, 227–232.

4. Rajasekaran, S.; Rao, G.K.; Pai, S.; Ranjan, A. Design, synthesis, anti-bacterial and in vitro anti-oxidant activity of substituted 2H-benzopyran-2-one derivatives. Int. J. ChemTech Res. 2011, 3, 555–559.

5. Pophale, R.A.; Deodhar, M.N. Synthesis and evaluation of novel phthalimide derivatives as analgesic and anti-inflammatory agents. Der Pharm. Chem. 2010, 2, 185–193.

6. Bhatnagar, A.; Sharma, P.K.; Kumar, N.; Upadhayay, A. Synthesis and in vitro evaluation of anti-oxidant and anti-inflammatory activity of 3-[4,5-dihydro-(5-substituted phenyl)-1H-pyrazol-3-yl]-2H-chromen2-one derivatives. Pharm. Chem. J. 2012, 46, 482–487.

7. Bansode, T.N.; Shelke, J.V.; Dongre, V.G. Synthesis and antimicrobial activity of some new N-acyl substitutedphenothiazines. Eur. J. Med. Chem. 2009, 44, 5094–5098.

8. Siddiqui, N.J.; Idrees, M.; Khati, N.T.; Dhond, M.G. Synthesis and anti-microbial activities of some new pyrazoles, oxadiazoles and isoxazole bearing benzofuran moiety. S. Afr. J. Chem. 2013, 66, 248–253.

9. Anthony, P.; Bashir, N.; Parveen, R. Regioselectivesynthesisof 1,4-disubstituted 1,2,3-bistriazoles and their anti-fungal and anti-oxidant evaluation. Asian J. Biomed. Pharm. Sci. 2014, 4, 9–13.

10. Bosquesi, P.L.; Melo, T.R.F.; Vizioli, E.O.; Santos, J.L.; Chung, M.C. Anti-inflammatory drug design using a molecular hybridization approach. Pharmaceuticals 2011, 4, 1450–1474.

11. Kaur, J.; Bhardwaj, A.; Huang, Z.; Knaus, E.E. N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation. Bioorg. Med. Chem. 2012, 22, 2154–2159.

12. Kaplancikli, Z.A.; Altintop, M.D.; Ozdemir, A.; Turan, Z.G.; Khan, S.I.; Tabanca, N. Synthesis and biological evaluation of some hydrazine derivatives as anti-inflammatory agents. Lett. Drug Des. Discov. 2012, 9, 310–315.

13. Kushwaha, T.A. Synthesis of novel 2-benzylbenzo[d]thazole-6-sulfonamide derivatives as potential anti-inflammatory agent. J. Chem. Pharm. Sci. 2014, 7, 34–38.

14. Shiradkar, M.R.; Ghodake, M.; Bothara, K.G.; Bhandari, S.V.; Nikalje, A.; Akula, K.C.; Desai, N.C.; Burange, P.J. Synthesis and anti-convulsant activity of clubbed thiazolidinone-barbituric acid and thiazolidinone–triazole derivatives. ARKIVOC 2007, XIV, 58–74.

15. Moffet, R.S. Central Nervous System Depressants. VII.1 pyridylcoumarins. J. Med. Chem. 1964, 7, 446–449.

16. Mavrova, A.T.; Wesselinova, D.; Tsenov, Y.A.; Denkova, P. Synthesis, cytotoxicity and effects of some 1,2,4-triazole and 1,3,4-thiadiazole derivatives on immunocompetent cells. Eur. J. Med. Chem. 2009, 44, 63–69.

17. Pertino, M.W.; Verdugo, V.; Theoduloz, C.; Hirschmann, G.S. Synthesis and anti-proliferative activity of some novel triazole derivatives from dehydroabietic acid. Molecules 2014, 19, 2523–2535.

18. Sharma, V.; Shrivastava, B.; Bhatia, R.; Bachwani, M.; Bachwani, M.; Khandelwal, R.; Ameta, J. Exploring potential of 1,2,4-triazole: A brief review. Pharmacol. Online 2011, 1, 1192–1222.
19. Lamie, P.F. Synthesis and anti-microbial activity of some novel isoindoline-1,3-dione derivatives. *J. Adv. Chem.* 2014, 8, 1660–1666.

20. Abdellatif, K.R.; Chowdhury, M.A.; Dong, Y.; Velázquez, C.; Das, D.; Suresh, M.R.; Knaus, E.E. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluromethyl-1H-pyrazole and its methanesulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies. *Bioorg. Med. Chem.* 2008, 16, 9694–9698.

21. RCSB Protein Data Bank. Available online: http://www.rcsb.org/pdb/home/home.do (accessed on 24 August 2015).

22. Abdellatif, K.R.; Huang, Z.; Chowdhury, M.A.; Kaufman, S.; Knaus, E.E. A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: Synthesis, biological evaluation and nitric oxide release studies. *Bioorg. Med. Chem. Lett.* 2011, 21, 3951–3956.

23. Seeley, H.W.; Van, D.P.J. *A Laboratory Manual of Microbiology*, 2nd ed.; Sons and Co: Bombay, India, 1975; pp. 55–80.

24. Ahmed, S.H.; Amin, M.A.; Saafan, A.E.; El-Gendy, A.O.; El-Gendy, A.O.; Islam, M. Measuring susceptibility of *Candida albicans* biofilms towards antifungal agents. *Der Pharm. Lett.* 2013, 5, 376–383.

25. El-Gendy, A.O.; Essam, T.M.; Amin, M.A.; Ahmed, S.H.; Nes, I.F. Clinical Screening for Bacteriocinogenic Enterococcus faecalis Isolated from Intensive Care Unit Inpatient in Egypt. *J. Microb. Biochem. Technol.* 2012, 4, 161–167.

26. Sader, H.S.; Flamm, R.K.; Jones, R.N. Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region. *Diagn. Microbiol. Infect. Dis.* 2013, 75, 417–422.

27. Tarek, N.; Hassan, H.M.; AbdelGhani, S.M.; Radwan, H.O.; El-Gendy, A.O. Comparative chemical and anti-microbial study of nine essential oils obtained from medicinal plants growing in Egypt. *Beni Suef Univ. J. Basic Appl. Sci.* 2014, 3, 149–156.

28. Ou, B.; Hampsch-Woodill, M.; Prior, R.L. Development and validation of improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. *J. Agric. Food Chem.* 2001, 49, 4619–4626.

29. Gridling, M.; Stark, N.; Madlener, S.; Lackner, A.; Popescu, R.; Benedek, B.; Diaz, R.; Tut, F.M.; Nha Vo, T.P.; Huber, D.; *et al*. *In vitro* anti-cancer activity of two ethno-pharmacological healing plants from Guatemala *Pluchea odorata* and *Phlebodium decumanum*. *Int. J. Oncol.* 2009, 34, 1117–1128.

30. Madlener, S.; Svacinova, J.; Kitner, M.; Kopecky, J.; Eytnr, R.; Lackner, A.; Vo, T.P.; Frisch, R.; Grusch, M.; de Martin, R.; *et al*. *In vitro* anti-inflammatory and anti-cancer activities of extracts of *Acalypha alopecuroidea* (Euphorbiaceae). *Int. J. Oncol.* 2009, 35, 881–891.

*Sample Availability*: Samples of the compounds 9, 12, 14, 15, 17a–c are available from the authors.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).